STAT

Font of despair: In the fierce competition for science funding, even a typeface glitch can be fatal

A doctor's "fatal error" was not medical but typographical: His funding request for a PTSD project on veterans didn't get past the VA's ruler-wielding enforcers of fonts and type size.

When he first saw the email, just after finishing rounds in the surgical intensive care unit, Dr. Joseph Schlesinger began to panic. A government staffer was writing to inform him that he’d made “a fatal error.”

Standing at the nurses’ pod, surrounded by patients in various states of post-surgical woe, he wondered what he should do next. Life-sustaining machines whirred around him, residents discussed prognoses — but he heard nothing. “It was like I was in a vacuum,” said Schlesinger, an assistant professor of anesthesiology and critical care medicine at Vanderbilt University and a staff physician at the Veterans Affairs medical center in Nashville. None of the cases in front of him needed his immediate attention, and so he left to address the crisis in his inbox.

His “fatal error” was not medical

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks